(Q52130333)

22 April 2018

title

No evidence of somatic FGFR3 mutation in various types of carcinoma. (English)

1 reference

22 April 2018

0 references

Karoui M

1

1 reference

22 April 2018

Hofmann-Radvanyi H

2

1 reference

22 April 2018

Zimmermann U

3

1 reference

22 April 2018

Couvelard A

4

1 reference

22 April 2018

Degott C

5

1 reference

22 April 2018

Faridoni-Laurens L

6

1 reference

22 April 2018

Ahomadegbe JC

7

1 reference

22 April 2018

Gazzeri S

8

1 reference

22 April 2018

Brambilla E

9

1 reference

22 April 2018

Clerici T

10

1 reference

22 April 2018

Charbonnier P

11

1 reference

22 April 2018

Tresallet C

12

1 reference

22 April 2018

Mitry E

13

1 reference

22 April 2018

Penna C

14

1 reference

22 April 2018

Rougier P

15

1 reference

22 April 2018

Boileau C

16

1 reference

22 April 2018

Thiery JP

17

1 reference

22 April 2018

Nordlinger B

18

1 reference

22 April 2018

Franc B

19

1 reference

22 April 2018

Radvanyi F

20

1 reference

22 April 2018

language of work or name

English

0 references

publication date

1 August 2001

1 reference

22 April 2018

published in

Oncogene

1 reference

22 April 2018

volume

20

1 reference

22 April 2018

issue

36

1 reference

22 April 2018

page(s)

5059-5061

1 reference

22 April 2018

https://scigraph.springernature.com/pub.10.1038/sj.onc.1204651

exact match

0 references

cites work

Frequent FGFR3 mutations in papillary non-invasive bladder (pTa) tumors

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204651

Frequent translocation t(4;14)(p16.3;q32.3) in multiple myeloma is associated with increased expression and activating mutations of fibroblast growth factor receptor 3

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204651

Spatio-temporal expression of FGFR 1, 2 and 3 genes during human embryo-fetal ossification.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204651

Graded activation of fibroblast growth factor receptor 3 by mutations causing achondroplasia and thanatophoric dysplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204651

RTK mutations and human syndromeswhen good receptors turn bad.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204651

Loss of heterozygosity at 4p16.3 and mutation of FGFR3 in transitional cell carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204651

A novel skeletal dysplasia with developmental delay and acanthosis nigricans is caused by a Lys650Met mutation in the fibroblast growth factor receptor 3 gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204651

FGFR activation in skeletal disorders: too much of a good thing

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204651

Somatic mutations of fibroblast growth factor receptor 3 (FGFR3) are uncommon in carcinomas of the uterine cervix.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204651

Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204651

inferred from DOI database lookup

7 January 2021

based on heuristic

Analysis of fibroblast growth factor receptor 3 S249C mutation in cervical carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204651

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1038/SJ.ONC.1204651

1 reference

22 April 2018

1 reference

22 April 2018